WARNER-LAMBERT NEURONTIN USE IN NON-EPILEPTIC CONDITIONS UNDER STUDY; ANTIDIABETIC TROGLITAZONE IN NIDDK TYPE II PREVENTION TRIAL, NDA SLATED FOR SUMMER
Executive Summary
One-quarter of the use of Warner-Lambert's anti-epileptic Neurontin (gabapentin) is for "conditions other than epilepsy," Parke-Davis Chairman Ronald Cresswell, PhD, told securities analysts April 11 in New York City. "We are aggressively investigating the effects of Neurontin on psychological conditions such as bipolar disorders and social phobias," Cresswell said. "We have begun multi-center pain studies in neuropathic pain and in post-herpetic neuralgia," he added. Sales of Neurontin in 1995 totaled $102 mil.